Financhill
Sell
32

GNFT Quote, Financials, Valuation and Earnings

Last price:
$4.17
Seasonality move :
-7.84%
Day range:
$4.10 - $4.18
52-week range:
$2.55 - $6.42
Dividend yield:
0%
P/E ratio:
32.57x
P/S ratio:
2.84x
P/B ratio:
2.85x
Volume:
1.5K
Avg. volume:
7.7K
1-year change:
-13.87%
Market cap:
$205M
Revenue:
$72.5M
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GNFT
Genfit SA
$151.2M -- -- -- $8.70
ADAP
Adaptimmune Therapeutics PLC
$6.6M -$0.17 -91.39% -8.33% $1.58
AKTX
Akari Therapeutics PLC
-- -$0.11 -- -- $7.00
CLLS
Cellectis SA
$13.8M -- 36.24% -100% $5.75
DBVT
DBV Technologies SA
$501.4K -$0.24 -- -87.99% $14.76
EDAP
Edap TMS SA
$16.6M -$0.17 -2.39% -4.81% $5.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GNFT
Genfit SA
$4.10 $8.70 $205M 32.57x $0.00 0% 2.84x
ADAP
Adaptimmune Therapeutics PLC
$0.24 $1.58 $64.2M -- $0.00 0% 0.35x
AKTX
Akari Therapeutics PLC
$1.19 $7.00 $38.3M -- $0.00 0% --
CLLS
Cellectis SA
$1.33 $5.75 $133.4M -- $0.00 0% 2.72x
DBVT
DBV Technologies SA
$9.10 $14.76 $248.9M -- $0.00 0% --
EDAP
Edap TMS SA
$1.71 $5.75 $63.9M -- $0.00 0% 0.95x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GNFT
Genfit SA
-- -0.565 -- --
ADAP
Adaptimmune Therapeutics PLC
-211.44% 3.737 50.03% 1.57x
AKTX
Akari Therapeutics PLC
-- -3.002 -- --
CLLS
Cellectis SA
30.41% 0.232 56.64% 1.64x
DBVT
DBV Technologies SA
-- -3.453 -- --
EDAP
Edap TMS SA
17.49% -0.684 10.79% 1.16x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GNFT
Genfit SA
-- -- -- -- -- --
ADAP
Adaptimmune Therapeutics PLC
$6.4M -$44.1M -107.36% -199.63% -619.47% -$67.8M
AKTX
Akari Therapeutics PLC
-- -$3.5M -- -- -- -$2.2M
CLLS
Cellectis SA
$8.6M -$14.2M -35.55% -49.15% -152.19% -$17.6M
DBVT
DBV Technologies SA
-- -$26.6M -- -- -- -$19.7M
EDAP
Edap TMS SA
$6M -$6.3M -43.34% -49.1% -44.23% -$6.6M

Genfit SA vs. Competitors

  • Which has Higher Returns GNFT or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -- compared to Genfit SA's net margin of -653.18%. Genfit SA's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    GNFT
    Genfit SA
    -- -- --
    ADAP
    Adaptimmune Therapeutics PLC
    87.93% -$0.18 -$12M
  • What do Analysts Say About GNFT or ADAP?

    Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 112.26%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.58 which suggests that it could grow by 550.54%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Genfit SA, analysts believe Adaptimmune Therapeutics PLC is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GNFT
    Genfit SA
    1 0 0
    ADAP
    Adaptimmune Therapeutics PLC
    3 3 0
  • Is GNFT or ADAP More Risky?

    Genfit SA has a beta of 1.148, which suggesting that the stock is 14.837% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.243, suggesting its more volatile than the S&P 500 by 124.255%.

  • Which is a Better Dividend Stock GNFT or ADAP?

    Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GNFT or ADAP?

    Genfit SA quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Genfit SA's net income of -- is lower than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.84x versus 0.35x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GNFT
    Genfit SA
    2.84x 32.57x -- --
    ADAP
    Adaptimmune Therapeutics PLC
    0.35x -- $7.3M -$47.6M
  • Which has Higher Returns GNFT or AKTX?

    Akari Therapeutics PLC has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat Akari Therapeutics PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GNFT
    Genfit SA
    -- -- --
    AKTX
    Akari Therapeutics PLC
    -- -- --
  • What do Analysts Say About GNFT or AKTX?

    Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 112.26%. On the other hand Akari Therapeutics PLC has an analysts' consensus of $7.00 which suggests that it could grow by 488.24%. Given that Akari Therapeutics PLC has higher upside potential than Genfit SA, analysts believe Akari Therapeutics PLC is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GNFT
    Genfit SA
    1 0 0
    AKTX
    Akari Therapeutics PLC
    1 0 0
  • Is GNFT or AKTX More Risky?

    Genfit SA has a beta of 1.148, which suggesting that the stock is 14.837% more volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.247, suggesting its less volatile than the S&P 500 by 75.292%.

  • Which is a Better Dividend Stock GNFT or AKTX?

    Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GNFT or AKTX?

    Genfit SA quarterly revenues are --, which are smaller than Akari Therapeutics PLC quarterly revenues of --. Genfit SA's net income of -- is lower than Akari Therapeutics PLC's net income of -$3.7M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.84x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GNFT
    Genfit SA
    2.84x 32.57x -- --
    AKTX
    Akari Therapeutics PLC
    -- -- -- -$3.7M
  • Which has Higher Returns GNFT or CLLS?

    Cellectis SA has a net margin of -- compared to Genfit SA's net margin of -170.14%. Genfit SA's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    GNFT
    Genfit SA
    -- -- --
    CLLS
    Cellectis SA
    81.09% -$0.18 $167M
  • What do Analysts Say About GNFT or CLLS?

    Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 112.26%. On the other hand Cellectis SA has an analysts' consensus of $5.75 which suggests that it could grow by 332.33%. Given that Cellectis SA has higher upside potential than Genfit SA, analysts believe Cellectis SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GNFT
    Genfit SA
    1 0 0
    CLLS
    Cellectis SA
    1 2 0
  • Is GNFT or CLLS More Risky?

    Genfit SA has a beta of 1.148, which suggesting that the stock is 14.837% more volatile than S&P 500. In comparison Cellectis SA has a beta of 2.924, suggesting its more volatile than the S&P 500 by 192.353%.

  • Which is a Better Dividend Stock GNFT or CLLS?

    Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GNFT or CLLS?

    Genfit SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.7M. Genfit SA's net income of -- is lower than Cellectis SA's net income of -$18.1M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.84x versus 2.72x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GNFT
    Genfit SA
    2.84x 32.57x -- --
    CLLS
    Cellectis SA
    2.72x -- $10.7M -$18.1M
  • Which has Higher Returns GNFT or DBVT?

    DBV Technologies SA has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GNFT
    Genfit SA
    -- -- --
    DBVT
    DBV Technologies SA
    -- -$1.30 --
  • What do Analysts Say About GNFT or DBVT?

    Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 112.26%. On the other hand DBV Technologies SA has an analysts' consensus of $14.76 which suggests that it could grow by 62.18%. Given that Genfit SA has higher upside potential than DBV Technologies SA, analysts believe Genfit SA is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GNFT
    Genfit SA
    1 0 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is GNFT or DBVT More Risky?

    Genfit SA has a beta of 1.148, which suggesting that the stock is 14.837% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.624, suggesting its less volatile than the S&P 500 by 162.448%.

  • Which is a Better Dividend Stock GNFT or DBVT?

    Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GNFT or DBVT?

    Genfit SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Genfit SA's net income of -- is lower than DBV Technologies SA's net income of -$27.1M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.84x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GNFT
    Genfit SA
    2.84x 32.57x -- --
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
  • Which has Higher Returns GNFT or EDAP?

    Edap TMS SA has a net margin of -- compared to Genfit SA's net margin of -52.18%. Genfit SA's return on equity of -- beat Edap TMS SA's return on equity of -49.1%.

    Company Gross Margin Earnings Per Share Invested Capital
    GNFT
    Genfit SA
    -- -- --
    EDAP
    Edap TMS SA
    42.01% -$0.20 $45.2M
  • What do Analysts Say About GNFT or EDAP?

    Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 112.26%. On the other hand Edap TMS SA has an analysts' consensus of $5.75 which suggests that it could grow by 236.26%. Given that Edap TMS SA has higher upside potential than Genfit SA, analysts believe Edap TMS SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GNFT
    Genfit SA
    1 0 0
    EDAP
    Edap TMS SA
    0 2 0
  • Is GNFT or EDAP More Risky?

    Genfit SA has a beta of 1.148, which suggesting that the stock is 14.837% more volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.015, suggesting its less volatile than the S&P 500 by 98.469%.

  • Which is a Better Dividend Stock GNFT or EDAP?

    Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GNFT or EDAP?

    Genfit SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $14.3M. Genfit SA's net income of -- is lower than Edap TMS SA's net income of -$7.4M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.84x versus 0.95x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GNFT
    Genfit SA
    2.84x 32.57x -- --
    EDAP
    Edap TMS SA
    0.95x -- $14.3M -$7.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Is TTD The Big Winner If Pharma Ads Are Banned?
Is TTD The Big Winner If Pharma Ads Are Banned?

Last week, Senators Bernie Sanders and Angus King introduced a…

Is Palantir Stock Overvalued?
Is Palantir Stock Overvalued?

By every traditional yardstick, including a price‑to‑sales well above 100,…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
11
VEON alert for Jun 14

VEON [VEON] is down 18.57% over the past day.

Buy
74
DAVE alert for Jun 14

Dave [DAVE] is down 12.68% over the past day.

Buy
54
DAR alert for Jun 14

Darling Ingredients [DAR] is up 9.12% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock